Free Delivery Over $100
|
|
|||
|
||||
OverviewChapter 1 examines the actions of drug companies in raising prescription drug prices in the United States, as well as the effects of these actions on the Federal and state budgets, and on American families. Chapter 2 addresses frequently asked questions about government and private-sector policies that affect drug prices and availability. Among the prescription drug topics covered are federally funded research and development, regulation of direct-to-consumer advertising, legal restrictions on reimportation, and federal price negotiation. The 340B Drug Pricing Program requires drug manufacturers to sell outpatient drugs at discounted prices to covered entities-eligible clinics, hospitals, and others-in order to have their drugs covered by Medicaid. Covered entities are only allowed to provide 340B drugs to certain eligible patients. Chapter 3 reviews the Health Resources and Services Administration's (HRSA) oversight of the 340B Program to ensure compliance with program rules. In 2017, nearly 60% of U.S. adults aged 18-64 reported being prescribed medication in the past 12 months. Approximately 70% of prescription medications carry out-of-pocket costs. Strategies to reduce prescription drug costs at the individual level are discussed in chapters 4 and 5. Each year, Americans pay more for prescription drugs, and rising drug prices have a disproportionate impact on older Americans. Chapter 6 examines the history of rising drug prices for the brand-name drugs most commonly prescribed for seniors. Generic drugs-copies of brand-name drugs-lead to significant cost savings. Before a generic drug can be marketed, FDA must approve the generic drug application. According to FDA, applications go through an average of three cycles of review before being approved, which may take years. Chapter 7 examines 1) the first review cycle approval rate of generic drug applications in recent years and factors that may have contributed to whether applications were approved; and 2) changes FDA has made to increase the first review cycle approval rate. Full Product DetailsAuthor: Elias B. ToftPublisher: Nova Science Publishers Inc Imprint: Nova Science Publishers Inc Weight: 0.506kg ISBN: 9781536176681ISBN 10: 1536176680 Pages: 248 Publication Date: 13 March 2020 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: In stock  We have confirmation that this item is in stock with the supplier. It will be ordered in for you and dispatched immediately. Table of ContentsPreface; Examining the Actions of Drug Companies in Raising Prescription Drug Prices; Frequently Asked Questions About Prescription Drug Pricing and Policy; Drug Discount Program: Status of Agency Efforts to Improve 340B Program Oversight; Strategies Used by Adults Aged 1864 to Reduce Their Prescription Drug Costs, 2017; Strategies Used by Adults Aged 65 and Over to Reduce Their Prescription Drug Costs, 20162017; Manufactured Crisis: How Devastating Drug Price Increases Are Harming Americas Seniors; Generic Drug Applications: FDA Should Take Additional Steps to Address Factors That May Affect Approval Rates in the First Review Cycle; Index.ReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |
||||
